|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2005
The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis
1 Dept of Medicine, Division of Pulmonary and Critical Care Medicine, and 2 Dept of Biostatistics, University of Washington, Seattle, WA, USA
CORRESPONDENCE: G. Raghu, Chest Clinic, Interstitial Lung Disease, Sarcoid and Pulmonary Fibrosis Program, University of Washington Medical Center, Box 356522, BB-1253 HSC, 1959 NE Pacific Street, Seattle, WA 98195-6522, USA. Fax: 1 2066858673. E-mail: graghu@u.washington.edu
Keywords: Idiopathic pulmonary fibrosis, interstitial lung disease, pulmonary function, survival, walk test
Received: December 11, 2003
Accepted August 30, 2004
Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive disease with a median survival of
The study population consisted of 28 patients with well-characterised progressive IPF. The timed walk test and concurrent measures of disease severity were assessed at baseline. Participants were prospectively followed for
There were strong correlations between the end-exercise saturation and walk-velocity parameters of the timed walk test and diffusing capacity, and arterial oxygen tension at rest. In univariate Cox proportional-hazards models, end-exercise saturation, change in saturation with exercise, walk distance and walk velocity were associated with survival. In unadjusted logistic regression models, odds of death at 2 yrs were associated with the same parameters.
In conclusion, the timed walk test relates to disease severity and long-term outcome in progressive idiopathic pulmonary fibrosis.
3 yrs. Measurements of airflow and lung volumes at rest are generally used to monitor the clinical course in this disorder. This study was designed to determine if a modified version of the 6-min walk test, called the timed walk test, accurately characterises disease severity and survival in IPF. 
4 yrs to determine the relationship between parameters of the timed walk test and survival.
This article has been cited by other articles:
|
|
 |
|
  J J Swigris, X Zhou, F S Wamboldt, R du Bois, R Keith, A Fischer, G P Cosgrove, S K Frankel, D Curran-Everett, and K K Brown Exercise peripheral oxygen saturation (Spo2) accurately reflects arterial oxygen saturation (Sao2) and predicts mortality in systemic sclerosis Thorax, July 1, 2009; 64(7): 626 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Fell, L. X. Liu, C. Motika, E. A. Kazerooni, B. H. Gross, W. D. Travis, T. V. Colby, S. Murray, G. B. Toews, F. J. Martinez, et al. The Prognostic Value of Cardiopulmonary Exercise Testing in Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., March 1, 2009; 179(5): 402 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Lynch III Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia/Fibrosis, and Sarcoidosis ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 635 - 686. [Full Text] [PDF]
|
|
|
|
|
|
A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui Interstitial lung disease guideline Thorax, September 1, 2008; 63(Suppl_5): v1 - v58. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Bourbonnais and L. Samavati Clinical predictors of pulmonary hypertension in sarcoidosis Eur. Respir. J., August 1, 2008; 32(2): 296 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Han, S. Murray, C. D. Fell, K. R. Flaherty, G. B. Toews, J. Myers, T. V. Colby, W. D. Travis, E. A. Kazerooni, B. H. Gross, et al. Sex differences in physiological progression of idiopathic pulmonary fibrosis Eur. Respir. J., June 1, 2008; 31(6): 1183 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A E Holland, C J Hill, M Conron, P Munro, and C F McDonald Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease Thorax, June 1, 2008; 63(6): 549 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Giannakoulas, T. D. Karamitsos, G. Pitsiou, and H. I. Karvounis Right ventricular dysfunction and functional limitation in idiopathic pulmonary fibrosis Eur. Respir. J., January 1, 2008; 31(1): 219 - 220. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Zisman, A. S. Karlamangla, D. J. Ross, M. P. Keane, J. A. Belperio, R. Saggar, J. P. Lynch III, A. Ardehali, and J. Goldin High-Resolution Chest CT Findings Do Not Predict the Presence of Pulmonary Hypertension in Advanced Idiopathic Pulmonary Fibrosis Chest, September 1, 2007; 132(3): 773 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Nathan, P. W. Noble, and R. M. Tuder Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension: Connecting the Dots Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 875 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. U. Wells and C. M. Hogaboam Update in Diffuse Parenchymal Lung Disease 2006 Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 655 - 660. [Full Text] [PDF]
|
|
|
|
|
|
H. R. Collard, K. J. Anstrom, M. I. Schwarz, and D. A. Zisman Sildenafil Improves Walk Distance in Idiopathic Pulmonary Fibrosis Chest, March 1, 2007; 131(3): 897 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hamada, S. Nagai, S. Tanaka, T. Handa, M. Shigematsu, T. Nagao, M. Mishima, M. Kitaichi, and T. Izumi Significance of Pulmonary Arterial Pressure and Diffusion Capacity of the Lung as Prognosticator in Patients With Idiopathic Pulmonary Fibrosis Chest, March 1, 2007; 131(3): 650 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. O. Villalba, P. D. Sampaio-Barros, M. C. Pereira, E. M. F. P. Cerqueira, C. A. Leme Jr, J. F. Marques-Neto, and I. A. Paschoal Six-Minute Walk Test for the Evaluation of Pulmonary Disease Severity in Scleroderma Patients Chest, January 1, 2007; 131(1): 217 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O.J. Dempsey, K.M. Kerr, L. Gomersall, H. Remmen, and G.P. Currie Idiopathic pulmonary fibrosis: an update QJM, October 1, 2006; 99(10): 643 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Flaherty, A.-C. Andrei, S. Murray, C. Fraley, T. V. Colby, W. D. Travis, V. Lama, E. A. Kazerooni, B. H. Gross, G. B. Toews, et al. Idiopathic Pulmonary Fibrosis: Prognostic Value of Changes in Physiology and Six-Minute-Walk Test Am. J. Respir. Crit. Care Med., October 1, 2006; 174(7): 803 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Lederer, S. M. Arcasoy, J. S. Wilt, F. D'Ovidio, J. R. Sonett, and S. M. Kawut Six-Minute-Walk Distance Predicts Waiting List Survival in Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., September 15, 2006; 174(6): 659 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Martinez and M. P. Keane Update in diffuse parenchymal lung diseases 2005. Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1066 - 1071. [Full Text] [PDF]
|
|
|
|
|
|
C. J. Lettieri, S. D. Nathan, S. D. Barnett, S. Ahmad, and A. F. Shorr Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis Chest, March 1, 2006; 129(3): 746 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Raghu, S. T.-Y. Yang, C. Spada, J. Hayes, and C. A. Pellegrini Sole Treatment of Acid Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis: A Case Series Chest, March 1, 2006; 129(3): 794 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Martinez Idiopathic Interstitial Pneumonias: Usual Interstitial Pneumonia versus Nonspecific Interstitial Pneumonia. Proceedings of the ATS, January 1, 2006; 3(1): 81 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Kim, H. R. Collard, and T. E. King Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proceedings of the ATS, January 1, 2006; 3(4): 285 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Martinez and K. Flaherty Pulmonary function testing in idiopathic interstitial pneumonias. Proceedings of the ATS, January 1, 2006; 3(4): 315 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Izumi, S. Mizuguchi, Y. Inagaki, S. Saika, N. Kawada, Y. Nakajima, K. Inoue, S. Suehiro, S. L. Friedman, and K. Ikeda BMP-7 opposes TGF-{beta}1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2 Am J Physiol Lung Cell Mol Physiol, January 1, 2006; 290(1): L120 - L126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Demedts, J. Behr, R. Buhl, U. Costabel, R. Dekhuijzen, H. M. Jansen, W. MacNee, M. Thomeer, B. Wallaert, F. Laurent, et al. High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis. N. Engl. J. Med., November 24, 2005; 353(21): 2229 - 2242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Johnson and G. Raghu Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures Eur. Respir. J., November 1, 2005; 26(5): 755 - 758. [Full Text] [PDF]
|
|
|
|
|
|
G. Tino Clinical Year in Review III: Sleep-disordered Breathing, Interstitial Lung Disease, Lung Transplantation, and Pediatric Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 251 - 254. [Full Text] [PDF]
|
|
|
|
|
|
G. Raghu Poor Choice of Primary Outcome in a Clinical Trial of Pirfenidone in Patients with IPF Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1229 - 1230. [Full Text] [PDF]
|
|
|
|
|
|
A. Azuma, T. Nukiwa, E. Tsuboi, M. Suga, S. Abe, K. Nakata, Y. Taguchi, S. Nagai, H. Itoh, M. Ohi, et al. Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 1040 - 1047. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |